{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:38:12Z","timestamp":1785580692579,"version":"3.56.0"},"reference-count":10,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the safety and efficacy of avacopan for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A systematic review of the literature was performed using the terms avacopan OR tavneos OR CCX168 OR ANCA-associated vasculitis in PubMed and Google Scholar. Articles between January 2016 and January 2023 were considered for inclusion. Bibliographies and ClinicalTrials.gov were also searched for completion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Relative English language and human studies related to pharmacology, clinical trials, and safety were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>The 52-week ADVOCATE and 12-week CLEAR clinical trials evaluated the safety and efficacy of avacopan. The remission rate was 65.7% and 54.9% in the avacopan and placebo group, respectively, in the ADVOCATE trial. The Birmingham Vasculitis Activity Score improved by \u226550% in 86.4% of avacopan treated patients and 70% of prednisone treated patients in the CLEAR trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison With Existing Drugs:<\/jats:title>\n                    <jats:p>Glucocorticoids in combination with cyclophosphamide, azathioprine, and\/or rituximab have been a mainstay of ANCA-associated vasculitis treatment. However, short- and long-term medication-related adverse effects risk negative outcomes for patients. Avacopan may provide equivalent to better treatment with fewer side effects due to a reduction, if not elimination, of glucocorticoids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Avacopan used in isolation or combination is safe and effective for ANCA-associated vasculitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280231161592","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T08:39:40Z","timestamp":1679992780000},"page":"1449-1454","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis"],"prefix":"10.1177","volume":"57","author":[{"given":"Christopher","family":"Alihosseini","sequence":"first","affiliation":[{"name":"College of Osteopathic Medicine, New York Institute of Technology, Glen Head, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7141-9947","authenticated-orcid":false,"given":"Hannah","family":"Kopelman","sequence":"additional","affiliation":[{"name":"Advanced Dermatology and Cosmetic Surgery, Maitland, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory","family":"Zaino","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-6289","authenticated-orcid":false,"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"bibr1-10600280231161592","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071446"},{"key":"bibr2-10600280231161592","unstructured":"Qasim A, Patel JB. ANCA positive vasculitis. In: StatPearls. StatPearls Publishing; 2022. Accessed February 9, 2023. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554372\/"},{"key":"bibr3-10600280231161592","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00391-X"},{"key":"bibr4-10600280231161592","doi-asserted-by":"publisher","DOI":"10.1159\/000442323"},{"key":"bibr5-10600280231161592","unstructured":"Tavneos. Package insert. ChemoCentryx; 2021. Accessed January 7, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214487s000lbl.pdf"},{"key":"bibr6-10600280231161592","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164646"},{"key":"bibr7-10600280231161592","unstructured":"ChemoCentryx. A randomized, double-blind, active-controlled, Phase 3 study to evaluate the safety and efficacy of CCX168 (Avacopan) in patients with ANCA-associated vasculitis treated concomitantly with rituximab or cyclophosphamide\/azathioprine. clinicaltrials.gov; 2022. Accessed January 5, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02994927"},{"key":"bibr8-10600280231161592","unstructured":"ChemoCentryx. A randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis on background of cyclophosphamide or rituximab treatment. clinicaltrials.gov; 2020. Accessed January 5, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01363388"},{"key":"bibr9-10600280231161592","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11185"},{"key":"bibr10-10600280231161592","unstructured":"Tavneos prices, coupons, copay & patient assistance. Drugs.com. Accessed January 7, 2023. https:\/\/www.drugs.com\/price-guide\/tavneos"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231161592","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280231161592","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231161592","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:06Z","timestamp":1777374786000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/10600280231161592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1177\/10600280231161592"],"URL":"https:\/\/doi.org\/10.1177\/10600280231161592","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]}}}